慢性阻塞性肺疾病并发肺动脉高压的研究进展(5)
[25]Nana-Sinkam SP，Lee JD，Sotto-Santiago S，et al.Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke[J].Am J Respir Crit Care Med，2007，175(7)：676-685.
[26]Milara J，Gabarda E，Juan G，et al.Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries[J].Eur Respir J，2012，39(4)：927-938.
[27]Stolz D，Rasch H，Linka A，et al.A randomised，controlled trial of bosentan in severe COPD[J].Eur Respir J，2008，32(3)：619-628.
[28]Valerio G，Bracciale P，Grazia DA.Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease[J].Ther Adv Respir Dis，2009，3(1)：15-21.
[29]Chen X，Tang S，Liu K，et al.Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension： a systematic review and meta-analysis[J].J Thorac Dis，2015，7(3)：309-319.
[30]Ghofrani HA，Staehler G，Grunig E，et al.Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease[J].Pulm Circ，2015，5(2)：296-304.
[31]Ghofrani HA，Humbert M，Langleben D，et al.Riociguat：mode of action and clinical development in pulmonary hypertension[J].Chest，2017，151(2)：468-480.
[32]Pichl A，Sommer N，Bednorz M，et al.Riociguat for treatment of pulmonary hypertension in COPD—a translational study[J].Eur Respir J，2019，53(6)：pii： 1802445.
(收稿日期：2019-04-04 本文編辑：许俊琴), http://www.100md.com(舒微 梁民勇 向明钧)
[26]Milara J，Gabarda E，Juan G，et al.Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries[J].Eur Respir J，2012，39(4)：927-938.
[27]Stolz D，Rasch H，Linka A，et al.A randomised，controlled trial of bosentan in severe COPD[J].Eur Respir J，2008，32(3)：619-628.
[28]Valerio G，Bracciale P，Grazia DA.Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease[J].Ther Adv Respir Dis，2009，3(1)：15-21.
[29]Chen X，Tang S，Liu K，et al.Therapy in stable chronic obstructive pulmonary disease patients with pulmonary hypertension： a systematic review and meta-analysis[J].J Thorac Dis，2015，7(3)：309-319.
[30]Ghofrani HA，Staehler G，Grunig E，et al.Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease[J].Pulm Circ，2015，5(2)：296-304.
[31]Ghofrani HA，Humbert M，Langleben D，et al.Riociguat：mode of action and clinical development in pulmonary hypertension[J].Chest，2017，151(2)：468-480.
[32]Pichl A，Sommer N，Bednorz M，et al.Riociguat for treatment of pulmonary hypertension in COPD—a translational study[J].Eur Respir J，2019，53(6)：pii： 1802445.
(收稿日期：2019-04-04 本文編辑：许俊琴), http://www.100md.com(舒微 梁民勇 向明钧)